A Child with Frequent Neurological Relapses
A six-year-old boy was presented with the diagnosis of left-sided hemiparesis and facial nerve paralysis. The findings showed multiple well-defined focal lesions bilaterally in the right, parietal region and the child was being treated with methylprednisolone followed by oral prednisolone. This was followed by several relapses, including recurrent episodes of limb weakness and facial nerve […]
Dermoid Cyst Concomitant with Focal Cortical Dysplasia
A 17-year-old girl presented with drug-resistant epilepsy since the age of 13. She often experienced impaired awareness seizures which rarely proceeded to bilateral tonic-clonic seizures. EEG had left temporal focal slowing without epileptiform discharges while a week long video-EEG showed no changes but the patient complained of olfactory aura. Her MRI was consisted with dermoid […]
An Umbrella of Clinical Manifestations
A 7-year-old boy was presented with a diagnosis of attention deficit hyperactivity disorder. The patient was hyperactive and had the impression of difficulty with eye contact. He also had mild motor tics disorder and IQ of 76%. At 9 years, the mother reported that he turned speechless, especially when it came to interacting with strangers. […]
Adalimumab-Induced Primary Progressive Multiple Sclerosis
A 45-year-old woman was presented with progressive visual problems, gait impairment and urinary dysfunction. The patient had a history of Graves’ disease, Sjogren disease and cystic nodular acne for about a decade. Over the past 4 years, she had underwent adalimumab therapy with excellent clinical response. Her evaluation revealed MRI lesions typical for MS, positive […]
Effect of Deoxyribonuclease in the treatment of Alzheimer’s
A 77-year-old man was diagnosed with secondary to late onset Alzheimer’s disease. Fourteen months post the diagnosis, patient began treatment with 10 mg memantine. After thirteen months of treatment, patient’s scores on MMSE and FAST were 10 and 5 respectively. Further, significant deterioration of cognitive function was observed after 3 months. His current MMSE and […]
Ultra-Long-Acting Oral Antipsychotic for Treatment of Schizophrenia
A new phase II study suggested improved quality of life and treatment adherence in schizophrenic patients with a novel, ultra-long-acting formulation of risperidone (LYN-005). The study comprised of 32 schizophrenia patients received immediate-release (IR) risperidone 2 mg or 4 mg and were randomized to either of the four groups, IR risperidone-matched placebo and LYN-005 at […]